tocilizumab: clinical use

Prescribing considerations

• Confirm that the indication, route, device and age eligibility match the specific product licence.
• Screen for active infection and latent tuberculosis; consider recurrent infection, viral hepatitis risk, diverticulitis, intestinal ulceration, hepatic disease and immunisation status.
• Assess baseline neutrophils, platelets, liver tests and lipids; consider renal function in impaired patients.
• Account for suppressed CRP and inflammatory symptoms when evaluating possible infection.
• Record brand and batch number for traceability.
• Ensure training and supervised first administration before subcutaneous home use.

Contraindications and cautions

• Hypersensitivity to tocilizumab or a formulation excipient.
• Active severe infection, subject to the intravenous product's specific exception and precautions for its licensed COVID-19 indication.

Monitoring

• Clinical surveillance for infection, hypersensitivity, abdominal complications and hepatic injury.
• Full blood count, including neutrophils and platelets.
• ALT, AST and other liver tests as clinically indicated.
• Lipid profile after treatment begins and subsequent cardiovascular-risk management.
• Disease response using clinical assessment rather than CRP alone.

Clinical pharmacology

Tocilizumab is a recombinant humanised IgG1 monoclonal antibody that inhibits signalling through soluble and membrane-bound interleukin-6 receptors. By reversing inflammation-mediated suppression of hepatic CYP enzymes, it can reduce exposure to medicines metabolised through CYP3A4, CYP1A2 or CYP2C9.

Formulation and product differences

• Selected products include a subcutaneous pre-filled pen, a subcutaneous pre-filled syringe and an intravenous concentrate.
• Subcutaneous formulations cover rheumatoid arthritis, giant cell arteritis and specified juvenile idiopathic arthritis populations.
• The selected intravenous formulation additionally covers severe CAR T-cell-associated cytokine release syndrome and specified severe COVID-19, but not giant cell arteritis.
• Device handling, paediatric eligibility, excipients, diluents and permitted room-temperature storage differ by product.

Solution for infusion

Route: Intravenous

Strengths: 20 mg/mL

Injection

Route: Parenteral

Strengths: 162 mg